Plixorafenib

Plixorafenib (previously PLX8394, also FORE8394) is Fore Biotherapeutics' Phase 2 BRAF inhibitor designed to hit both classic V600 mutations and the harder-to-target class 2 BRAF alterations [1,4]. The FORTE master protocol NCT05503797 is enrolling up to 254 patients across solid tumors and gliomas carrying BRAF mutations, with objective response rate (ORR) as the primary endpoint [1]. The pitch: a 'paradox breaker' that avoids the dimerization-driven skin cancer signal limiting vemurafenib and dabrafenib, while extending activity to BRAF-altered tumors that current drugs miss. Fore disclosed a positive interim efficacy analysis in BRAF V600 recurrent primary CNS tumors and the FDA granted Breakthrough Therapy designation for high-grade glioma in 2025 [7], a meaningful regulatory tailwind. The commercial question is whether plixorafenib can carve out space in a market already populated by three approved BRAF inhibitors plus Day One Biopharmaceuticals' tovorafenib (Ojemda), which won pediatric low-grade glioma approval in 2024 as a competing paradox breaker [5]. Fore's bet is non-V600 BRAF cancers and recurrent gliomas - territory where standard BRAF drugs underperform or aren't approved.

Novel compound, never approved anywhere. Phase 2, currently recruiting at n=254 across three subprotocols (A, B, C) [1]. FDA designations confirmed: Fast Track for cancers with BRAF Class 1 (V600) and Class 2 (including fusions) alterations after exhaustion of prior therapies; Orphan Drug for primary brain and CNS malignancies; and Breakthrough Therapy designation (BTD) for high-grade glioma granted in 2025 following a positive interim efficacy analysis from the FORTE BRAF V600 recurrent primary CNS tumor cohort [7,8]. Phase 1/2a data (NCT02012231) reported a 66.7% overall ORR across BRAF-altered solid tumors with median duration of response 13.9 months; in the subset of MAPK-inhibitor-naive BRAF V600 recurrent primary CNS tumors (n=9), ORR was ~67% with clinical benefit rate >75% [8]. This is the efficacy foundation that justified the Phase 2 master protocol. Two supporting studies are active: NCT06610682, a Johns Hopkins investigator-led early-phase trial testing plixorafenib alone or with retifanlimab (Incyte's PD-1 inhibitor) for BRAF-altered glioma, using CSF circulating tumor DNA as a pharmacodynamic readout [2]; and NCT06385119, a completed Phase 1 food-effect and drug-drug interaction study with cobicistat, a strong CYP3A4 inhibitor used as a probe to characterize metabolic liability [3]. Fore Biotherapeutics is private, with $113M total raised in Series D financing including a $38M Series D-2 in May 2025 from SR One, Medicxi, OrbiMed, HBM, Wellington, Novartis Venture Fund, Cormorant, and 3B Future Health Fund [9]. No SEC filings or earnings call commentary available. No top-line readout date for the master protocol has been disclosed publicly; based on NCT05503797 opening recruitment in 2022 and the rare biomarker populations involved, full enrollment likely runs into 2027 with rolling subprotocol readouts at major oncology meetings before then. The most actionable near-term datapoint will be subprotocol-level ORR, especially Subprotocol B (non-V600 BRAF) and the glioma cohort in Subprotocol C.

BRAF is a kinase, a protein that adds phosphate groups to other proteins, sitting in the MAP kinase cascade - the pathway cells use to decide when to grow and divide. When BRAF carries the V600E mutation (the most common cancer-driving change), it gets stuck signaling 'grow' continuously, driving melanoma, colorectal cancer, thyroid cancer, and a chunk of pediatric brain tumors. First-generation BRAF inhibitors (vemurafenib, dabrafenib, encorafenib) bind the mutant protein and shut it off in melanoma cells. They have a known catch: in cells with wild-type BRAF, the drug paradoxically activates the pathway by pushing RAF proteins into dimers that signal even harder. This is why patients on these drugs grow squamous cell skin cancers, and why the drugs don't work for class 2 BRAF alterations - non-V600 activating mutations (including BRAF fusions and splice variants) that already signal as dimers [4]. Plixorafenib (PLX8394) was engineered to block BRAF without forcing dimer formation, the so-called paradox-breaker design demonstrated in the original Zhang et al. Nature 2015 paper [4]. The target is well-validated: BRAF as a cancer driver has 20+ years of genetics behind it and four approved drugs hitting it. The open question is whether paradox-breaking translates into meaningfully better efficacy in the patient populations where first-gen drugs fall short.

NCT05503797 (FORTE) is a master protocol with three parallel subprotocols, recruiting up to 254 patients [1]. Subprotocol A covers solid tumors with class 1 (V600) BRAF alterations after prior BRAF/MEK inhibitor therapy. Subprotocol B targets class 2 BRAF alterations, the dimerization-dependent mutations that first-gen drugs cannot reach. Subprotocol C enrolls recurrent or progressive primary CNS tumors with BRAF alterations. Primary endpoint is objective response rate per RECIST (Response Evaluation Criteria in Solid Tumors, the standardized framework for measuring tumor shrinkage in solid cancers) or RANO (Response Assessment in Neuro-Oncology, the equivalent standard for brain tumors). No randomized comparator - single-arm signal-finding design, standard for biomarker-selected oncology Phase 2. Sponsor is Fore Biotherapeutics. Class 2 BRAF mutations are rare overall, occurring in roughly 0.7% of all cancers and ~16.5% of BRAF-mutant tumors, but concentrate in specific histologies: they make up 50-80% of BRAF mutations in non-small cell lung cancer and 22-30% in colorectal cancer [10]. This shapes enrollment feasibility - Subprotocol B depends on broad molecular testing infrastructure to identify eligible patients. The design is reasonable for a paradox-breaker hypothesis: it isolates the populations where differentiation should be visible (post-BRAF inhibitor V600, class 2, glioma) rather than competing head-to-head against entrenched standard of care in front-line melanoma. The risk is that single-arm ORR at modest per-cohort sample sizes makes regulatory go/no-go decisions ambiguous unless responses are deep and durable. For accelerated approval in glioma, FDA has accepted single-arm ORR plus duration of response before; tovorafenib's 2024 approval in pediatric low-grade glioma was based on this kind of evidence [5].

Our model gives this drug a 12% chance of eventually being approved. That starting point comes from the historical approval rate for Phase 2 drugs in this area, which runs about 13%. A non-randomized trial design and more secondary endpoints than usual nudge the estimate up slightly, while a thin sponsor approval record and weak earlier-phase results pull it back down. The remaining factors fall close to average for this stage, so the final number stays near where it started.

Efficacy risk: the master protocol pools heterogeneous tumor types, and a positive overall signal could mask which subprotocol actually worked. Class 2 BRAF mutations are biologically diverse, with some responding to MEK inhibition and others not, and a single-arm ORR may not separate true paradox-breaking activity from underlying tumor biology. Safety risk: paradox-breaker design should reduce squamous cell carcinomas relative to vemurafenib and dabrafenib, but plixorafenib's full safety profile in larger cohorts isn't public yet, though Phase 1 reported drug-related discontinuation rate under 2% [8]. Drug-drug interactions are a concern; the cobicistat study [3] (cobicistat is a strong inhibitor of CYP3A4, a liver enzyme that metabolizes many drugs) characterizes CYP3A4 sensitivity, which matters for CNS tumor patients often on enzyme-inducing anti-seizure medications. Execution risk: Fore is a private biotech with $113M raised through Series D financings [9] - well-capitalized for a focused asset but a 254-patient master protocol is capital-intensive. Enrollment in BRAF class 2 cohorts is genuinely hard because these mutations occur in only ~0.7% of all cancers, requiring broad NGS testing infrastructure to find them [10]. Commercial risk: tovorafenib (Day One Bio) won pediatric low-grade glioma in 2024 with strong response data and owns the paradox-breaker narrative in pediatric CNS [5]. For adult solid tumors with BRAF V600, encorafenib + binimetinib in melanoma and encorafenib + cetuximab in colorectal cancer are entrenched [6]. Plixorafenib needs a clear win in class 2 disease or recurrent glioma to be commercially relevant.

Worth watching, narrowly but now more seriously than the base-rate model suggested. The 2025 Breakthrough Therapy designation for high-grade glioma is a real signal that FDA viewed the interim FORTE CNS data favorably [7]. The signals that matter most going forward are ORR in Subprotocol B (class 2 BRAF) and the glioma cohort of Subprotocol C, because those are the populations where current drugs fail and where paradox-breaking is the actual hypothesis being tested. ORR in V600 post-BRAF-inhibitor patients is interesting but commercially crowded. Check back when Fore presents updated subprotocol-level ORR data at a major oncology meeting (ASCO, ESMO, or the Society for Neuro-Oncology (SNO) annual meeting for the CNS arm). The Johns Hopkins glioma study [2] is the more interesting near-term mechanistic readout because the CSF circulating tumor DNA endpoint gives a clean pharmacodynamic answer about whether plixorafenib is actually engaging BRAF inside CNS tumors - a question first-gen BRAF inhibitors never answered well. Fore being private means no quarterly visibility; conference presentations, any new financing round, or partnership/M&A news will be the main signal source. If a large pharma partners on rights or buys the program before key data, that's a strong read-through on the data. Estimated catalyst window: subprotocol-level efficacy updates likely 2026-2027, with the V600 CNS arm furthest along given the BTD.